OUTCOMES MANAGEMENT IN A REAL WORLD EVIDENCE CONTEXT. THE CASE OF ABIRATERONE AND ENZALUTAMIDE IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

• Type: Other Publications
• Date: 2019

Authors

Cardoso, P (Author) Other; Santos, C (Author) Other; Costa, F (Author) Other; Gonçalves F (Author) FMUP

Other information

Authenticus ID: P-00R-FZN

DOI: 10.36401/jqsh-19-39

Abstract (EN): <jats:title>ABSTRACT</jats:title> <jats:p>At present, for patients with metastatic and castration-resistant prostate cancer, European Society for Medical Oncology and National Comprehensive Cancer Network guidelines recommend enzalutamide (E) or abiraterone (A). There are still a few studies comparing both drugs in a real-world setting, thus, in this article, we discuss an outcomes management methodology, supporting the follow-up of patients. This involves measuring relevant baseline traits and outcomes, such as overall survival (OS), treatment duration, patient-reported outcomes, and adverse events. We include 38 men in the A group and 15 in the E group. When comparing the survival of both drugs, both present similar OS. Regarding the quality-of-life analysis (QoL) with EPIC26, reported Standard QoL score was 58.3% in our patients, which was in line with the European Organization for the Research and Treatment of Cancer reference. As a result, by showing that we can capture the distinctive clinical benefits of A and E, and that patient-reported outcomes can be systematically collected for more than 2 years per living patient, we can now incorporate these findings in clinical discussions, risk-sharing agreements, or policy-level arguments.</jats:p>

Language: English

Type (Professor's evaluation): Scientific